On March 31, 2026, Imunon, Inc. (IMNN) announced financial results for the fourth quarter and full year 2025 and provided a business update. The company announced that the Phase 3 OVATION 3 trial remains ahead of plan, supported by the strong interest from principal investigators and patients in an indication that has not seen appreciable advancements in frontline standard of care for over 30 years. Imunon also recently highlighted the final data assessment from the Phase 2 OVATION 2 trial that showed treatment with IMNN-001 was associated with an overall survival benefit of more than a year and more than two years for patients also receiving PARP inhibitors as maintenance therapy. In February 2026 the company announced a strategic reorganization with plans to reduce operating expenses while committing its full resources to advancing the OVATION 3 trial.
